Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients
Status:
Completed
Trial end date:
2020-06-10
Target enrollment:
Participant gender:
Summary
To examine the effects of adding prandial Afrezza inhaled insulin to patients with type 2
diabetes who are not controlled after at least 6 months of other diabetes treatments
including oral agents, basal insulin, or GLP-1 use.